Current status and future directions of anti-angiogenic therapy for gliomas
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current status and future directions of anti-angiogenic therapy for gliomas
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 18, Issue 3, Pages 315-328
Publisher
Oxford University Press (OUP)
Online
2016-02-25
DOI
10.1093/neuonc/nov180
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma
- (2015) Martin J.B. Taphoorn et al. JOURNAL OF CLINICAL ONCOLOGY
- Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma
- (2015) Christine Lu-Emerson et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma
- (2015) Victor A. Levin et al. JOURNAL OF NEURO-ONCOLOGY
- Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma
- (2015) Ulrik Lassen et al. NEURO-ONCOLOGY
- Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)
- (2015) Andrew B. Lassman et al. NEURO-ONCOLOGY
- Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model
- (2015) Véronique Mathieu et al. NEOPLASIA
- Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†
- (2014) B. Chauffert et al. ANNALS OF ONCOLOGY
- Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
- (2014) J. Schwarzenberg et al. CLINICAL CANCER RESEARCH
- Resistance to Antiangiogenic Therapy
- (2014) Shiao-Pei Weathers et al. Current Neurology and Neuroscience Reports
- Microenvironmental Clues for Glioma Immunotherapy
- (2014) Michael Platten et al. Current Neurology and Neuroscience Reports
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- MGMT testing—the challenges for biomarker-based glioma treatment
- (2014) Wolfgang Wick et al. Nature Reviews Neurology
- O10.04 * THE RANDOMIZED, MULTICENTER GLARIUS TRIAL INVESTIGATING BEVACIZUMAB/IRINOTECAN VS STANDARD TEMOZOLOMIDE IN NEWLY DIAGNOSED, MGMT-NON-METHYLATED GLIOBLASTOMA PATIENTS: FINAL SURVIVAL RESULTS AND QUALITY OF LIFE
- (2014) U. Herrlinger et al. NEURO-ONCOLOGY
- BI-32 * RISK FACTOR ANALYSIS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WHO DID NOT RECEIVE SALVAGE THERAPY
- (2014) W. Wick et al. NEURO-ONCOLOGY
- AT-18 * SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])
- (2014) T. Cloughesy et al. NEURO-ONCOLOGY
- Immunotherapy advances for glioblastoma
- (2014) D. A. Reardon et al. NEURO-ONCOLOGY
- Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma
- (2014) M. Nowosielski et al. NEUROLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab in Glioblastoma — Still Much to Learn
- (2014) Howard A. Fine NEW ENGLAND JOURNAL OF MEDICINE
- Primary Central Nervous System Lymphoma and Atypical Glioblastoma: Multiparametric Differentiation by Using Diffusion-, Perfusion-, and Susceptibility-weighted MR Imaging
- (2014) Philipp Kickingereder et al. RADIOLOGY
- Integrin control of the transforming growth factor-β pathway in glioblastoma
- (2013) Patrick Roth et al. BRAIN
- Delineating multiple functions of VEGF-A in the adult brain
- (2013) Tamar Licht et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
- (2013) Olivier L. Chinot et al. Current Neurology and Neuroscience Reports
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Statins and the Risk of Death in Patients With Prostate Cancer
- (2013) Oriana Yu et al. JOURNAL OF CLINICAL ONCOLOGY
- Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy
- (2013) Kyrre E Emblem et al. NATURE MEDICINE
- Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation
- (2013) W. Wick et al. NEURO-ONCOLOGY
- Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain
- (2013) F. Graus et al. NEURO-ONCOLOGY
- Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma
- (2013) Emeline Tabouret et al. NEURO-ONCOLOGY
- A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)
- (2013) Markus Hutterer et al. NEURO-ONCOLOGY
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
- (2013) T. T. Batchelor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis
- (2013) Tobias V. Lanz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer
- (2012) Andreas G Niethammer et al. BMC CANCER
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- Detection of glioblastoma response to temozolomide combined with bevacizumab based on µMRI and µPET imaging reveals [18F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy
- (2012) Aurélien Corroyer-Dulmont et al. NEURO-ONCOLOGY
- Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment
- (2012) M Weiler et al. ONCOGENE
- Bevacizumab for Progressive Vestibular Schwannoma in Neurofibromatosis Type 2
- (2012) Scott R. Plotkin et al. OTOLOGY & NEUROTOLOGY
- Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs
- (2012) E.-M. E. Hedlund et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Current concepts and management of glioblastoma
- (2011) Matthias Preusser et al. ANNALS OF NEUROLOGY
- Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion
- (2011) A. G. Sorensen et al. CANCER RESEARCH
- Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept
- (2011) J. F. de Groot et al. CLINICAL CANCER RESEARCH
- Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells
- (2011) L. von Baumgarten et al. CLINICAL CANCER RESEARCH
- Discriminant Analysis of 18F-Fluorothymidine Kinetic Parameters to Predict Survival in Patients with Recurrent High-Grade Glioma
- (2011) M. Wardak et al. CLINICAL CANCER RESEARCH
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
- (2011) John F. de Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells
- (2011) S. Grau et al. JOURNAL OF NEURO-ONCOLOGY
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria
- (2011) A. Radbruch et al. NEURO-ONCOLOGY
- Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
- (2011) W. B. Pope et al. NEUROLOGY
- Reversible modulations of neuronal plasticity by VEGF
- (2011) T. Licht et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Bevacizumab does not increase the risk of remote relapse in malignant glioma
- (2010) Antje Wick et al. ANNALS OF NEUROLOGY
- Recent Advances in Therapy for Glioblastoma
- (2010) Jennifer Clarke et al. ARCHIVES OF NEUROLOGY
- Angiopoietin-2 Interferes with Anti-VEGFR2-Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas
- (2010) S.-S. Chae et al. CLINICAL CANCER RESEARCH
- Bevacizumab and Recurrent Malignant Gliomas: A European Perspective
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
- (2010) Roger Stupp et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
- (2010) Wolfgang Wick et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
- (2010) Elizabeth R. Gerstner et al. JOURNAL OF NEURO-ONCOLOGY
- Hypoxia inducible factor stabilization leads to lasting improvement of hippocampal memory in healthy mice
- (2009) Bartosz Adamcio et al. BEHAVIOURAL BRAIN RESEARCH
- Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma
- (2009) David A. Reardon et al. CANCER
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
- (2009) Walid S. Kamoun et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study
- (2009) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
- (2009) Gregor Dresemann et al. JOURNAL OF NEURO-ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
- (2009) Scott R. Plotkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Integrin αvβ3in Gliomas Correlates with Tumor Grade and Is not Restricted to Tumor Vasculature
- (2008) Oliver Schnell et al. BRAIN PATHOLOGY
- Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
- (2008) David A. Reardon et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
- (2008) A. D. Norden et al. NEUROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started